CEL-SCI Corporation news

   Watch this stock
Showing stories 1 - 10 of about 87   

Articles published

CVM 1.85 +0.06 (3.35%)
price chart
Cel-Sci Corporation: The Arbitration Is On, But Is The Phase III Trial Off?
I've gone through fur or five significant redrafts of this article since I started trying to get it organized at the end of August, and each time I thought I had captured a good representation of the current situation for Cel-Sci Corp. (NYSEMKT:CVM ...
A Closer Look At Cel-Sci Corporation Going Into Spring Of 2016
Cel-Sci Corporation (NYSEMKT:CVM) is on the verge of several significant milestones and inflection points during the first several months of 2016.
CEL-SCI Corporation Releases Letter to Shareholders
CEL-SCI initiated the proceedings against the former CRO in October 2013 and is seeking payment for damages related to the former CRO's prior involvement in the Phase 3 clinical trial of Multikine.
CEL-SCI Announces Reverse Stock Split
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announced today that during its annual Shareholder's Meeting on June 12, 2017, a 1-for-25 reverse split was authorized for its outstanding shares of common stock.
CEL-SCI Corp (CVM) Says FDA Requested Changes to Multikine Investigator Brochure
On June 28, 2017 CEL-SCI Corporation received a letter from the U.S. Food and Drug Administration (FDA) in response to CEL-SCI's most recent June 2, 2017 submission regarding the clinical hold imposed on the Company's Phase 3 head and neck cancer ...
CEL-SCI Corporation (NYSEMKT:CVM): What Is Price Telling Us?
CEL-SCI Corporation (NYSEMKT:CVM) has had a noteworthy run year to date. The company started out 2017 at around $0.07 a share, and has since gained to trade above $0.11 - a 60% gain across the period.
The Saga Of CEL-SCI Corporation (NYSEMKT:CVM)'S Bleak Clinical Trials  Journal Transcript
CEL-SCI Announces Update on Arbitration against Former Clinical Research ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American:CVM) announced today an update on its arbitration with its former clinical research organization (CRO).
Vanguard Group Inc built an about 0.93% stake in CEL-SCI Corporation (CVM)  Post Analyst
CEL-SCI Announces Update on Ongoing Arbitration against Former Clinical ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that as it nears the conclusion of its arbitration with its former clinical research organization (CRO), the Company has restructured its agreement with the ...
CEL-SCI Announces $1.5 Million NIH SBIR Grant to Support Development of ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that it has been awarded a new Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Arthritis and Musculoskeletal and Skin ...
US FDA Removes Clinical Hold on CEL-SCI's Phase 3 Head & Neck Cancer Trial
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced it has received a letter from the U.S.
CEL-SCI Corporation (CVM) Stock: Gaining Big On FDA News  CNA Finance (press release)
FDA lifts hold on Cel-Sci's clinical trial for head and neck cancer drug  Washington Business Journal